Table 1.

Number of Participants Contributing to Pooled Efficacy and Safety Populations, According to Age

Study	Efficacy Population						Safety Population
	<75			≥75			<75			≥75
	Placebo	Canagliflozin 100 mg	Canagliflozin 300 mg	Placebo	Canagliflozin 100 mg	Canagliflozin 300 mg	Non‐canagliflozin	Canagliflozin 100 mg	Canagliflozin 300 mg	Non‐canagliflozin	Canagliflozin 100 mg	Canagliflozin 300 mg
Monotherapy	186	189	192	6	6	5	186	189	192	6	6	5
Add‐on to metformin	183	364	363	0	4	4	543	364	363	6	4	4
Add‐on to metformin and sulfonylurea	154	150	154	2	7	2	154	150	154	2	7	2
Add‐on to metformin and pioglitazone	108	109	108	7	4	6	108	109	108	7	4	6
CANVAS add‐on to insulin substudy	531	530	539	34	36	48	—	—	—	—	—	—
CANVAS add‐on to sulfonylurea substudy	42	38	35	3	4	5	—	—	—	—	—	—
Add‐on to metformin vs glimepiride	—	—	—	—	—	—	475	469	476	7	14	9
Older adults (55–80)	—	—	—	—	—	—	225	221	222	12	20	14
Moderate renal impairment (estimated glomerular filtration rate 30 to <50 mL/min per 1.73 m2)	—	—	—	—	—	—	68	66	70	22	24	19
CANVAS (all)	—	—	—	—	—	—	1,348	1,361	1,328	93	84	113
Total	1,204	1,380	1,391	52	61	70	3,107	2,929	2,913	155	163	172

CANVAS = CANagliflozin cardioVascular Assessment Study.